Original StudyMyD-88 L265P MUTATIONS ARE PRESENT IN SOME CASES OF VITREORETINAL LYMPHOMAPulido, Jose S. MD, MS, MPH, MBA*,†; Salomao, Diva R. MD‡; Frederick, Lori A. BS‡; Viswanatha, David S. MD‡Author Information Departments of *Ophthalmology, †Molecular Medicine, and ‡Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. Reprint requests: Jose S. Pulido, MD, MS, MPH, MBA, Departments of Ophthalmology and Molecular Medicine, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905; e-mail: [email protected] Supported in part by unrestricted grants from Research to Prevent Blindness Inc, NY, and from the Deshong Family. Presented at the Atlantic Coast Retina Meeting, Boston, MA, September 1, 2015. None of the authors have any conflicting interests to disclose. Retina: April 2015 - Volume 35 - Issue 4 - p 624-627 doi: 10.1097/IAE.0000000000000589 Buy Metrics AbstractIn Brief Purpose: To determine whether Myd88 L265P mutations occur in diffuse large B-cell vitreoretinal lymphomas. Methods: The formalin-fixed paraffin-embedded cells from three patients with classic clinical findings of vitreoretinal lymphoma that also had histologic confirmation were evaluated using a validated amplification-refractory mutation system polymerase chain reaction to determine the presence of the mutation. Results: The 74 ± 2 base pair product seen from the mutated Myd-88 protein was noted in 2 of the 3 cases. Conclusion: Myd-88 L265P constitutive activating mutations are present in at least some cases of the diffuse large B-cell lymphoma form of vitreoretinal lymphoma. Further studies on the incidence of this mutation in retinal lymphomas are warranted. In two of three cases of vitreoretinal lymphoma with classic clinical findings and histopathologic findings of diffuse large B-cell lymphoma, an Myd-88 L265P mutation was found. Myd88 L265P mutations are seen in at least some cases of vitreoretinal lymphoma. © 2015 by Ophthalmic Communications Society, Inc.